| scholarly article | Q13442814 |
| P50 | author | Bernard A. Lafont | Q37649405 |
| P2093 | author name string | Vanessa M Hirsch | |
| Alicia Buckler-White | |||
| Takeo Kuwata | |||
| Ilnour Ourmanov | |||
| Robert Goeken | |||
| Simoy Goldstein | |||
| Ranjani Iyengar | |||
| P2860 | cites work | High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR | Q22242246 |
| The hope for an HIV vaccine based on induction of CD8+ T lymphocytes--a review | Q24630490 | ||
| Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection | Q24645815 | ||
| Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome | Q24648628 | ||
| The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? | Q24652185 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes | Q29616210 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection | Q29619099 | ||
| Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection | Q29619124 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
| Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f | Q57075677 | ||
| Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques | Q57089570 | ||
| Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile | Q58477195 | ||
| HIV vaccine failure prompts Merck to halt trial | Q59098676 | ||
| CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause? | Q59375800 | ||
| Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 | Q64378954 | ||
| Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species | Q70540344 | ||
| Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination | Q73097737 | ||
| Six mamu-A locus alleles defined by a polymerase chain reaction sequence specific primer method | Q73200142 | ||
| Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes | Q80643935 | ||
| Development of an AIDS vaccine: a daunting epidemiological challenge | Q81578580 | ||
| HIV vaccines | Q82900063 | ||
| Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques. | Q51988506 | ||
| HIV pathogenesis: the first cut is the deepest. | Q51992672 | ||
| Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. | Q51993308 | ||
| Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA | Q56930699 | ||
| The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. | Q30367176 | ||
| Flow cytometric analysis of live cell proliferation and phenotype in populations with low viability | Q30809854 | ||
| Post-infection immunodeficiency virus control by neutralizing antibodies | Q33288264 | ||
| Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. | Q33645053 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. | Q33781055 | ||
| Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques | Q33781916 | ||
| Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. | Q33782797 | ||
| Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge | Q33799497 | ||
| Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV | Q33800033 | ||
| Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques | Q33800760 | ||
| Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques | Q33819493 | ||
| Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells | Q33844334 | ||
| Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen | Q33850281 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Ad | Q33998310 | ||
| Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention | Q34050736 | ||
| CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype | Q34142932 | ||
| Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies | Q34150125 | ||
| Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine | Q34339365 | ||
| Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. | Q34391256 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies | Q34970873 | ||
| Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. | Q35023525 | ||
| Loss of naïve cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques. | Q35634983 | ||
| Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication | Q35785115 | ||
| Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know | Q35852348 | ||
| Antiviral antibodies are necessary for control of simian immunodeficiency virus replication | Q35857503 | ||
| Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine | Q35857531 | ||
| Mamu-B*08-positive macaques control simian immunodeficiency virus replication | Q35947708 | ||
| T cell vaccines for microbial infections | Q36090185 | ||
| Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge | Q36228649 | ||
| Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection | Q36229666 | ||
| Perils at mucosal front lines for HIV and SIV and their hosts | Q36274922 | ||
| Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer | Q36285910 | ||
| Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. | Q36368095 | ||
| HIV disease: fallout from a mucosal catastrophe? | Q36398125 | ||
| Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. | Q36399551 | ||
| Immunopathogenesis of acute AIDS virus infection | Q36497211 | ||
| Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys | Q36628390 | ||
| HIV-1 vaccine development: progress and prospects | Q36718578 | ||
| Correlates of immune protection and the development of a human immunodeficiency virus vaccine | Q36950597 | ||
| Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans | Q36971813 | ||
| Anti-HIV adaptive immunity: determinants for viral persistence | Q37139709 | ||
| Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge | Q37297052 | ||
| Nonreplicating vaccinia vector efficiently expresses recombinant genes | Q37299518 | ||
| Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses | Q37483781 | ||
| AIDS. Resource needs for HIV/AIDS. | Q39440791 | ||
| A Convenient and Economical Freezing Procedure for Mononuclear Cells | Q39561931 | ||
| Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein | Q39608920 | ||
| Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. | Q40291422 | ||
| Pathogenic diversity of simian immunodeficiency viruses | Q40692683 | ||
| DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques | Q40904272 | ||
| Role of complement and Fc receptors in the pathogenesis of HIV-1 infection | Q41413269 | ||
| Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells | Q41491967 | ||
| Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence | Q41684943 | ||
| Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients | Q41689302 | ||
| Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. | Q44022556 | ||
| Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge | Q44097571 | ||
| Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes | Q44666320 | ||
| The locus encoding an oligomorphic family of MHC-A alleles (Mane-A*06/Mamu-A*05) is present at high frequency in several macaque species | Q44882196 | ||
| Compact, synthetic, vaccinia virus early/late promoter for protein expression. | Q45108318 | ||
| Pathogenesis of HIV infection: what the virus spares is as important as what it destroys | Q45419109 | ||
| Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses | Q45730388 | ||
| Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity | Q45734062 | ||
| An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants | Q45735721 | ||
| Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
| Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys | Q45749710 | ||
| Development and homeostasis of T cell memory in rhesus macaque | Q45882091 | ||
| CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection | Q46200257 | ||
| Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope | Q46331384 | ||
| HIV vaccine design and the neutralizing antibody problem | Q46474020 | ||
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate | Q46775963 | ||
| AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope | Q47289180 | ||
| T-cell dynamics during acute SIV infection | Q47747277 | ||
| Estimating resource needs for HIV/AIDS health care services in low-income and middle-income countries. | Q47987756 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Vaccinia virus | Q1986297 | ||
| immunization | Q1415366 | ||
| Simian immunodeficiency virus | Q1890246 | ||
| P304 | page(s) | 5388-5400 | |
| P577 | publication date | 2009-03-25 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody | |
| P478 | volume | 83 |
| Q33519507 | A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease |
| Q36827328 | Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses |
| Q35069126 | Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques |
| Q36827377 | Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock |
| Q36978847 | Influence of mismatch of Env sequences on vaccine protection by live attenuated simian immunodeficiency virus |
| Q33696406 | Isolation of Potent Neutralizing Monoclonal Antibodies from an SIV-Infected Rhesus Macaque by Phage Display |
| Q37785949 | Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. |
| Q42153006 | Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques. |
| Q34701202 | Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. |
| Q41876895 | Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques |
| Q35076961 | Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen |
| Q33680119 | TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species |
| Q35382944 | The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys |
| Q47398548 | Truncating the Gp41 Cytoplasmic Tail of SIV Decreases Sensitivity to Neutralizing Antibodies without Increasing Envelope Content of Virions |
| Q35531553 | Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus |
Search more.